The GI Cancer Institute saves lives by funding Gastro-Intestinal (GI) cancer research.
GI cancers include those of the oesophagus, stomach, liver, gall bladder, pancreas and bowel. GI cancers are the most common form of cancer, affecting 24,600 Australians each year and claiming a devastating 33 lives each day.
Our clinical trials allow us to find better ways to treat GI cancers. This has seen improvement in both the life expectancy and quality of life of people diagnosed with these cancers.
Donations are used to fund clinical trials research by the not-for-profit organisation Australasian Gastro-Intestinal Trials Group (AGITG).
The GI Cancer Institute and the AGITG run clinical trials for pancreatic cancer patients around Australia. It is important to ask your medical oncologist about which clinical trials are suitable for you.
The GI Cancer Institute and the AGITG is dedicated to saving, improving and extending the lives of GI cancer patients.
P: 1300 666 769
The GAP clinical trial
This study aims to determine the effect of pre-operative chemotherapy in patients with resectable pancreatic cancer. Patients may be eligible to join this study if they are aged 18 years or more and have been diagnosed with cancer of the pancreas for which they plan to undergo surgery.
All participants in this trial will undergo pre-operative chemotherapy with the drugs gemcitabine and nab-paclitaxel.
The trial is currently in follow-up stage and not open to patients at this time.